News

Location:Home > News > Industry news
Oral OTEZLA? (Apremilast) Monotherapy Showed Long-Term Clinical Benefits in DMARD-Na?ve Patients with Active Psoriatic Arthritis
Author:admin  Source:  AddDate:2014-07-28

Clinically meaningful improvements in enthesitis, dactylitis and physical function with OTEZLA seen at week 16 and were sustained for up to 52 weeks of treatment

PALACE 4 is the first and only large randomized, placebo-controlled study to examine the efficacy and safety of a single agent in patients na?ve to previous DMARD therapy

Long-term safety and tolerability profile with OTEZLA consistent with previous PALACE studies

BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results from a long-term (52-week) phase III trial of OTEZLA, the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), in psoriatic arthritis patients who have not had prior treatment with systemic or biologic disease-modifying antirheumatic drugs (DMARDs). The data were presented at the European League Against Rheumatism Annual Congress (EULAR 2014) in Paris, France.

"Physicians need a variety of options to treat psoriatic arthritis, as treatment is highly individualized and some patients may not be appropriate candidates for biologics or certain systemic therAPIes," said Alvin Wells, M.D., Ph.D., director, Rheumatology and Immunology Center, Franklin, MN. "These efficacy and safety results suggest that OTEZLA monotherapy has the potential to be used for adults with active psoriatic arthritis in the first-line setting, prior to the initiation of DMARD therapy, and possibly as a long-term treatment option."


Previous:Null
Next:Merck Strengthens Commitment to ...
Share:
apex英雄官网手游 体球网比分 排列三组六普通 云南快乐十分 加盟真的赚钱么 六合图库 天津快乐十分走势图快 吃鸡游戏大全 中国足彩网即时指数 新疆25选7开奖号 360彩票app官方版 球探体育比分即时足球比分 地下城与勇士最新版本赚钱 lol赚钱不 实况nba比分数据 在那个网站看竞彩比分 梦幻西游转区查询